An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

The biotech has named Jamie Coleman its chief commercial officer ... she served as vice president of brand marketing for Zepbound, during which time she oversaw the accelerated launch of the ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Competitor Zepbound (tirzepatide) is a smidge cheaper at $1,086.37 ... called “Sick of the System.” The minute-long commercial is abrasive, even chaotic, which is presumably the point. Set to Childish ...

Eli Lilly, the manufacturer of Mounjaro and Zepbound, did not immediately respond to a request for comment. While reports of vision problems in patients taking semaglutide and tirzepatide are rare ...

The ad promotes, without identifying, semaglutide, the compounded versions of the weight-loss drugs Ozempic and Wegovy, and tirzepatide, the compounded version of Zepbound ... to provide safety ...

and global commercial leadership across therapeutic areas, including most recently serving as Vice President, U.S. Brand Leader for Zepbound®. “We are excited to welcome Jamie to the team as we ...